Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

por Das, Satya, Johnson, Douglas B.
Publicado 2019

Management of Acral and Mucosal Melanoma: Medical Oncology Perspective

por Jung, Seungyeon, Johnson, Douglas B
Publicado 2022

Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis

por Johnson, Douglas B., Menzies, Alexander M.
Publicado 2023

Pandemic medicine: the management of advanced melanoma during COVID-19

por Patrinely, James R, Johnson, Douglas B
Publicado 2020

MEK inhibitors in non-V600 BRAF mutations and fusions

por Johnson, Douglas B., Nebhan, Caroline A., Noel, Marcus S.
Publicado 2020

Long-term outcomes in patients with immune checkpoint inhibitor induced pneumonitis

por Davis Puente, Andrea, Johnson, Douglas B, Bastarache, Julie A
Publicado 2023

Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series

por Goodman, Rachel S, Jung, Seungyeon, Quintos, Jessica, Johnson, Douglas B
Publicado 2023

Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms

por Joseph, Gwenyth J., Johnson, Douglas B., Johnson, Rachelle W.
Publicado 2023

Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy

por Wong, Selina K., Nebhan, Caroline A., Johnson, Douglas B.
Publicado 2021

Balancing Cancer Immunotherapy Efficacy and Toxicity

por Johnson, Douglas B., Jakubovic, Baruch D., Sibaud, Vincent, Sise, Meghan E.
Publicado 2020

Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge

por Park, Benjamin C, Jung, Seungyeon, Wright, Jordan J, Johnson, Douglas B
Publicado 2022

Immune-checkpoint inhibitors: long-term implications of toxicity

por Johnson, Douglas B., Nebhan, Caroline A., Moslehi, Javid J., Balko, Justin M.
Publicado 2022

COVID-19: the Emerging Role of Medical Student Involvement

por Patrinely, James Randall, Zakria, Danny, Berkowitz, Sean T., Johnson, Douglas B., Totten, Douglas J.
Publicado 2020

Immune checkpoint inhibitors and their impact on liver enzymes and attenuation

por Park, Benjamin C., Lee, Aaron X. T., Ye, Fei, Turker, Isik, Johnson, Douglas B.
Publicado 2022

Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors

por Grad, Robert N, Jung, Seungyeon, Ye, Fei, Sun, Lili, Johnson, Douglas B, Agarwal, Rajiv
Publicado 2023

Clinically relevant genes and regulatory pathways associated with NRAS(Q61) mutations in melanoma through an integrative genomics approach

por Jiang, Wei, Jia, Peilin, Hutchinson, Katherine E., Johnson, Douglas B., Sosman, Jeffrey A., Zhao, Zhongming
Publicado 2014

Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates

por Wang, Yu, Johnson, Douglas B., Lu, Steve, Diaz, Luis A., Xu, Yaomin, Balko, Justin M.
Publicado 2019

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology

por Choucair, Khalil, Naqash, Abdul Rafeh, Nebhan, Caroline A, Nipp, Ryan, Johnson, Douglas B, Saeed, Anwaar
Publicado 2022

Cost assessment in melanoma clinical trials: A cross-sectional study

por Goodman, Rachel S., Garner, Desmond C., Koester, Stefan, Patrinely, J. Randall, Dewan, Anna K., Johnson, Douglas B.
Publicado 2023

COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

por Chen, Yu-Wei, Tucker, Matthew D., Beckermann, Kathryn E., Iams, Wade T., Rini, Brian I., Johnson, Douglas B.
Publicado 2021